Status:
UNKNOWN
BRAF V600E Mutations In Papillary Thyroid Carcinoma
Lead Sponsor:
Bezmialem Vakif University
Conditions:
Papillary Thyroid Carcinoma
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.
Detailed Description
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the averag...
Eligibility Criteria
Inclusion
- Patients with papillary thyroid cancer
Exclusion
- Patients who do not want to be a part of this study
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01417442
Start Date
July 1 2011
End Date
July 1 2012
Last Update
August 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yeliz Emine Ersoy
Istanbul, Istanbul, Turkey (Türkiye), 34308